Suchergebnisse - "Brown, Samuel M"

PubPharm (18)

1

Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024

enthalten in: MMWR. Morbidity and mortality weekly report | 2024

von DeCuir, J. | Payne, A. | Self, W. | +105

2

Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Kojima, N. | Adams, K. | Self, W. | +143

CommentIn: Clin Infect Dis. 2023 Aug 22;77(4):558-559. - PMID 37255313

3

Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source : Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022

enthalten in: Vaccine | 2023

von Surie, D. | Bonnell, L. | DeCuir, J. | +40

4

Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023

enthalten in: MMWR. Morbidity and mortality weekly report | 2023

von DeCuir, J. | Surie, D. | Zhu, Y. | +50

5

Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Tenforde, M. | Self, W. | Zhu, Y. | +58

6

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022

enthalten in: MMWR. Morbidity and mortality weekly report | 2022

von Surie, D. | DeCuir, J. | Zhu, Y. | +47

7

Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States

enthalten in: Vaccine | 2022

von Turbyfill, C. | Adams, K. | Tenforde, M. | +51

8

Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022

enthalten in: MMWR. Morbidity and mortality weekly report | 2022

von Surie, D. | Bonnell, L. | Adams, K. | +151

9

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States : living test negative design study

enthalten in: BMJ (Clinical research ed.) | 2022

von Adams, K. | Rhoads, J. | Surie, D. | +138

UpdateOf: medRxiv. 2022 Jun 14;:. - PMID 35734090

10

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Lewis, N. | Self, W. | Gaglani, M. | +54